Convergent Evolution in Aplastic Anemia: Independent HLA-Loss Clones Drive Remission Without Increasing Leukemia Risk
Key Insights
A landmark study of 619 patients reveals that blood stem cells in aplastic anemia (search) independently acquire protective mutations to evade autoimmune attack, with a median of three independent clones per patient.
HLA (search)-loss clones and CHIP mutations almost never co-occur in the same cells, suggesting HLA loss alone provides sufficient proliferative advantage without selecting for pre-leukemic mutations.
The findings challenge prior assumptions by showing these protective clones can arise years before diagnosis and are associated with long-lasting remission rather than increased cancer risk.
A transformative study published in Nature Genetics has fundamentally reshaped the understanding of how blood stem cells survive and repopulate the bone marrow in aplastic anemia (search), a rare and life-threatening blood disorder. Scientists at St. Jude Children's Research Hospital and collaborating institutions demonstrated that different blood stem cells within the same patient independently acquire genetic mutations that allow them to escape immune destruction—a process of convergent evolution that can restore blood production and lead to long-term remission without elevating the risk of progression to myelodysplastic syndrome (search) (MDS) or leukemia (search).
"We found that each patient with aplastic anemia (search) that escapes autoimmunity has multiple, independent genetic events in different blood stem cells that allow those cells to escape autoimmunity," said corresponding author Marcin Wlodarski, MD, PhD, of the St. Jude Department of Hematology. "Stem cells silence the risk HLA (search) allele through several mechanisms, and our data show that these events are protective, benign events that don't cause progression to MDS or leukemia (search), even when the rescued clones grow and dominate the bone marrow."
Convergent evolution in the bone marrow
The study analyzed bone marrow and blood samples from 619 patients with aplastic anemia (search)—256 children and 363 adults—representing the largest pediatric cohort of its kind reported to date. Overall, 69% of patients carried at least one acquired genetic change: HLA (search) mutations or uniparental isodisomy 6p (UPD6p) clones were found in 16% of patients, paroxysmal nocturnal hemoglobinuria (PNH) clones in 44%, and clonal hematopoiesis (CHIP) mutations in 21%.
Using single-cell DNA sequencing, the researchers profiled 304,902 individual cells from 48 samples, simultaneously analyzing mutations and cell-surface proteins. This approach revealed that protective mutations arise independently in different blood stem cells rather than accumulating sequentially within a single cell lineage.
The team expected to find one to three immune-escape events per individual. Instead, they discovered a median of three independent clones per patient, with one patient harboring 15 distinct clones—all resulting in loss of the risk HLA (search) allele. "Aplastic anemia (search) shows us convergent evolution in miniature: Multiple independent mutational events arise in different cells, all leading to the same escape from autoimmunity," Wlodarski said. "It shows the amazing nature of human hematopoiesis to cure itself from bad actors, like the autoimmune T cells, and reconstitute the bone marrow."
Pediatric versus adult mutation patterns
The study uncovered striking differences between pediatric and adult patients. Acquired mutations proved just as common in children as in adults, but in pediatric patients, 65% of CHIP mutations occurred in just three genes: BCOR (search), BCORL1 (search), and ASXL1 (search), compared with only 27% in adults. Since age-related CHIP mutations are not expected to preexist in children, these findings suggest the mutations represent immune-escape events acquired in direct response to the autoimmune attack.
Phylogenetic reconstruction using whole-genome sequencing of single blood stem cells yielded another unexpected finding: some HLA (search)-loss clones had arisen many years before clinical diagnosis. "We had expected that these mutations occur right before disease onset," Wlodarski noted. "But we found some of these HLA-loss clones arose many years before clinical diagnosis."
Protective clones and cancer risk
A critical finding with direct clinical implications emerged from the observation that clones harboring HLA (search) risk allele loss and those carrying CHIP mutations almost never co-occurred in the same cells. This mutual exclusivity indicates that HLA loss alone provides sufficient proliferative advantage, eliminating selective pressure for additional CHIP mutations that could predispose to MDS or leukemia (search).
"We saw that patients with blood stem cell clones that escape autoimmunity can improve their blood counts," Wlodarski said. "We also learned that these clones do not indicate an increased risk for leukemia (search). On the contrary, they often indicate the possibility of long-lasting remission."
The team also identified that long-lived, rescued clones exhibited higher expression of CD34 (search), a surface marker for blood stem and progenitor cells. This finding suggests CD34 enrichment could serve as a biomarker for long-lasting recovery, offering clinicians a potential tool to identify patients likely to achieve durable remission.
Complementary findings from the RACE trial
A separate study from King's College London, analyzing 197 patients with severe aplastic anemia (search) enrolled in the European RACE clinical trial, provided complementary insights into the genetic landscape of the disease. That study found that approximately one-third of patients already had detectable genetic mutations at diagnosis, with more than 70% showing detectable mutations two years after treatment.
Importantly, very few patients progressed to blood cancer—only three developed myeloid malignancies—suggesting that many identified mutations are likely harmless or low risk. The RACE study also demonstrated that the thrombopoietin receptor agonist eltrombopag did not appear to increase harmful genetic changes linked to cancer risk. Instead, researchers concluded the mutations largely reflect the stressed and damaged bone marrow environment inherent to aplastic anemia (search) itself.
The King's College team identified mutations in genes commonly associated with normal aging, including DNMT3A (search) and TET2 (search), which grow slowly and are not strongly linked to cancer progression. In contrast, mutations typically associated with aggressive blood cancers were relatively uncommon.
Clinical implications
Together, these findings challenge longstanding assumptions about clonal hematopoiesis in aplastic anemia (search). Rather than representing a harbinger of malignant transformation, the emergence of genetically distinct stem cell clones—particularly those involving HLA (search) loss—appears to be a protective, restorative mechanism. The convergent evolution observed across independent clones within individual patients underscores the bone marrow's remarkable capacity for self-repair when freed from autoimmune attack.
The research was supported by grants from the St. Jude Sumara Fellowship, the National Institutes of Health, the Edward P. Evans MDS Foundation, the German Federal Ministry of Education and Research, the American Society of Hematology, and the American Lebanese Syrian Associated Charities (ALSAC), among others.